Calithera Biosciences, Inc. (NASDAQ:CALA) clinical-stage biopharmaceutical, is expected to report third quarter earnings results, after market close, on Thursday 5th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.31 per share.
Looking ahead, the full year loss are expected at $ 1.29 per share.
Stock Performance
Shares of Calithera Biosciences, Inc. traded up $ 0.22 or 6.23 percent on Wednesday, reaching $ 3.75 with volume of 325.10 thousand shares. Calithera Biosciences, Inc. has traded high as $ 3.76 and has cracked $ 3.55 on the downward trend
The closing price of $ 3.75, representing a 18.06 % increase from the 52 week low of $ 2.99 and a 56.85 % decrease over the 52 week high of $ 8.18.
The company has a market capital of $ 264.60 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Calithera Biosciences, Inc. will be hosting a conference call at 5:00 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.calithera.com
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology.
